World News | EU Drug Agency Clears COVID-19 Therapeutics Ronapreve, Regkiron
Get latest articles and stories on World at LatestLY. The European Medicines Agency recommended on Thursday authorizing two antibody medicines, Ronapreve and Regkirona, for COVID-19 treatment in patients who are at risk of their disease becoming severe.
Brussels [Belgium], November 11 (ANI/Sputnik): The European Medicines Agency recommended on Thursday authorizing two antibody medicines, Ronapreve and Regkirona, for COVID-19 treatment in patients who are at risk of their disease becoming severe.
The agency's human medicines committee said the drugs were based on monoclonal antibodies, designed to block the binding of the virus's spike protein in the early stages of infection. Their use in patients who did not need ventilation reduced the number of hospitalizations.
"Ronapreve and Regkirona are the first monoclonal antibody medicines to receive a positive opinion from the CHMP for COVID-19," the agency said in a statement.
EMA will now send its recommendations for both medicines to the European Commission for a rapid legally binding decision.
Also Read | Yemen’s Houthi Militia Claim Responsibility for Ballistic Missile Attack on Saudi Military Base.
Health Commissioner Stella Kyriakides said the two medicines were from a shortlist of five treatments the EU hoped to authorize for use by the end of the year. Member states can already call upon the Commission's contract for 55,000 Ronapreve doses. (ANI/Sputnik)
(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)